Immunic (IMUX) Financials

Immunic remains a development-stage biotechnology company with no reported revenue across the periods provided. Its quarterly operating losses have generally remained in the $20 million to $33 million range, with a Q1 2026 net loss of $32.6 million—worse than the $19.3 million loss in Q4 2025 and the largest loss in the recent quarterly data.

Research and development remains the company’s largest expense, rising to $25.6 million in Q1 2026 from $19.1 million in Q4 2025. Selling, general and administrative expense also increased to $7.6 million from $4.3 million. The higher spending may support Immunic’s clinical development programs, but it also increases the company’s cash requirements while revenue remains absent.

Cash flow continues to reflect a pre-commercial biotechnology business. Operating cash outflow was $17.3 million in Q1 2026, compared with $19.3 million in Q4 2025 and $24.6 million in Q2 2025. Capital expenditures remain minimal, with only $2,000 spent on property and equipment in Q1 2026. However, Immunic has not generated positive operating cash flow in any of the reported quarters.

The balance sheet improved sharply during Q1 2026 because of financing activity. Cash and equivalents increased to $186.6 million from $35.1 million at Q3 2025, primarily after the company raised $187.3 million through common equity issuance. At the Q1 operating cash-burn rate, this cash balance represents roughly 10 to 11 quarters of operating funding before considering changes in spending, clinical milestones or additional financing. This is only an approximation, not a guarantee of future runway.

• Liquidity improved substantially: Cash and equivalents of $186.6 million at March 31, 2026 were nearly five times total current liabilities of $38.4 million, providing a stronger short-term liquidity position.
• Financing reduced near-term funding pressure: Immunic generated $188.6 million from financing activities in Q1 2026, mostly from equity issuance, compared with only $59,000 of net financing cash flow in Q4 2025.
• Operating cash burn moderated sequentially: Q1 2026 operating cash outflow of $17.3 million was lower than the $19.3 million outflow in Q4 2025 and the $24.6 million outflow in Q2 2025.
• Debt exposure appears limited in the latest quarter: The Q1 2026 financing data shows equity funding rather than new debt issuance, while noncurrent liabilities were only $146,000.
• R&D investment remains elevated: Research and development spending reached $25.6 million in Q1 2026, indicating continued investment in the pipeline but also sustaining a high cash-burn rate.
• Interest income provides a modest offset: Interest and investment income was $760,000 in Q1 2026, supported by the larger cash balance, but it covered only a small portion of the company’s operating expenses.
• Immunic has no operating revenue: Reported revenue was $0 in the available income statements, leaving the company dependent on financing and cash reserves to fund operations.
• Losses remain persistent: Net losses continued every quarter in the data set, and the Q1 2026 loss widened to $32.6 million from $19.3 million in Q4 2025.
• Accumulated losses are substantial: Retained earnings were negative $641.2 million at March 31, 2026, highlighting the long period of unprofitable operations.
• Shareholder dilution is a key risk: The $187.3 million Q1 equity raise increased the common stock balance materially. Reported weighted-average share counts are also highly volatile across periods, so investors should review the company’s detailed share-count and offering disclosures when assessing dilution.